Found: 22
Select item for more details and to access through your institution.
Antibody titers after SARS‐CoV‐2 mRNA vaccination in patients with aplastic anemia—A single‐center study.
- Published in:
- European Journal of Haematology, 2022, v. 108, n. 6, p. 528, doi. 10.1111/ejh.13756
- By:
- Publication type:
- Article
Internet‐based patient survey on the consequences of COVID‐19 lockdown on treatment and medical follow‐up of patients with aplastic anemia or paroxysmal nocturnal hemoglobinuria in Germany.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 5, p. 740, doi. 10.1111/ejh.13587
- By:
- Publication type:
- Article
Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.
- Published in:
- PLoS ONE, 2018, v. 13, n. 6, p. 1, doi. 10.1371/journal.pone.0197233
- By:
- Publication type:
- Article
Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 19, p. 7196, doi. 10.3390/ijms21197196
- By:
- Publication type:
- Article
Bosutinib in chronic myeloid leukemia: patient selection and perspectives.
- Published in:
- Journal of Blood Medicine, 2018, v. 9, p. 43, doi. 10.2147/JBM.S129821
- By:
- Publication type:
- Article
Comparison of flow‐FISH and MM–qPCR telomere length assessment techniques for the screening of telomeropathies.
- Published in:
- Annals of the New York Academy of Sciences, 2020, v. 1466, n. 1, p. 93, doi. 10.1111/nyas.14248
- By:
- Publication type:
- Article
The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1277453
- By:
- Publication type:
- Article
The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1277453
- By:
- Publication type:
- Article
Androgen derivatives improve blood counts and elongate telomere length in adult cryptic dyskeratosis congenita.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. 669, doi. 10.1111/bjh.16997
- By:
- Publication type:
- Article
Leukocyte Counts Based on DNA Methylation at Individual Cytosines.
- Published in:
- Clinical Chemistry, 2018, v. 64, n. 3, p. 566, doi. 10.1373/clinchem.2017.279935
- By:
- Publication type:
- Article
The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4210, doi. 10.3390/cancers13164210
- By:
- Publication type:
- Article
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0275-0
- By:
- Publication type:
- Article
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2775, doi. 10.1007/s00277-024-05867-w
- By:
- Publication type:
- Article
Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 4, p. 1149, doi. 10.1007/s00277-024-05650-x
- By:
- Publication type:
- Article
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 12, p. 3383, doi. 10.1007/s00277-023-05458-1
- By:
- Publication type:
- Article
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 10, p. 2741, doi. 10.1007/s00277-023-05394-0
- By:
- Publication type:
- Article
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 2, p. 349, doi. 10.1007/s00277-022-05080-7
- By:
- Publication type:
- Article
Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 12, p. 2655, doi. 10.1007/s00277-022-05000-9
- By:
- Publication type:
- Article
Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.
- Published in:
- PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0123476
- By:
- Publication type:
- Article
Transient elastography in adult patients with cryptic dyskeratosis congenita reveals subclinical liver fibrosis: a retrospective analysis of the Aachen telomere biology disease registry.
- Published in:
- 2021
- By:
- Publication type:
- journal article